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Objectives:  This  retrospective  study  aimed  to  assess  to  what  extent  an  adverse  drug  reaction  (ADR),
an  abnormal  therapeutic  drug  monitoring  (TDM)  or a  non-response,  was  attributable  to  an  abnormal
cytochrome  P450  activity  in a psychiatric  setting.
Method:  We collected  the  results  of  investigations  performed  in these  situations  related  to  psychotropic
drugs  between  January  2005  and  November  2014.  Activities  of  different  cytochrome  P450  were  assessed
by  genotyping  and/or  phenotyping.  Two  experienced  clinical  pharmacologists  assessed  independently
the  possible  association  between  the  event  and  the  results  of  the  investigations.
Results:  One  hundred  and  thirty  eight  clinical  or  biological  situations  had  a complete  assessment  of  all
major  metabolic  pathways  of  the  target  drug.  A majority  of clinical  or biological  situations  were  observed
with antidepressants  (n  = 93, 67.4%),  followed  by antipsychotics  (n = 28, 20.3%),  benzodiazepines  and  hyp-
notics  (n =  13, 9.4%),  and  psychostimulants  (n =  4,  2.9%).  Genotype  and/or  phenotype  determination  was
mainly  performed  because  of  ADRs  (n  = 68,  49.3%)  or  non-response  (n  =  46, 33.3%).  Inter-rater  reliability
of  the  scoring  system  between  the  pharmacologists  was  excellent  (kappa  = 0.94). The  probability  of an
association  between  ADR, TDM  or non-response  and  metabolic  status  was  rated as  intermediate  to  high
in  34.7%  of all cases,  with  proportions  of 30.4%  and 36.7%,  for non-response  and  ADR respectively.
Conclusion:  When  indicated  by clinical  pharmacologists,  ADR,  TDM  or non-response  may  be attributable
to  a  variation  of  the metabolic  status  with  an  intermediate  to  high  probability  in  34.7% of  patients,  based  on
the congruent  assessment  made  by two  clinical  pharmacologists.  Further  studies  assessing  the  clinical
relevance  of prospective  explorations  and  clarifying  the  appropriate  method  according  to  the clinical
context  are  needed.
©  2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
There is substantial unexplained interindividual variability inPlease cite this article in press as: C. Lloret-Linares, et al., Scr
activity in patients with therapeutic problems in a psychiat
http://dx.doi.org/10.1016/j.phrs.2016.07.002
rug response in the management of psychiatric disorders [1]. This
ariability can lead to lack of improvement, adverse drug reactions
ADR) as well as variability in time to respond to treatment. Vari-
 Poster presented at the 12th Congress of EACPT (EACPT 2015). 27–30 June 2015.
∗ Corresponding authors at: Psychopharmacology unit, Division of Clinical phar-
acology and toxicology, Geneva University Hospitals, Gabrielle Perret-Gentil 4,
211 Genève 4, Switzerland.
E-mail address: marie.besson@hcuge.ch (M.  Besson).
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043-6618/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ability may  bring a lack of adherence or put the patient at risk to
be deﬁnitely considered as resistant or intolerant. This will further
lead to the choice of another line of treatment, that is not always
needed, thus delaying the overall beneﬁt of the therapeutic regimen
[2,3]. Predicting variability and using therapeutic individualization
could increase the quality of care management [4,5]. Therefore,
strategies able to identify the factors of variability and to select
the appropriate drug or its adequate dosage represent promising
tools in the care of psychiatric disorders.eening for genotypic and phenotypic variations in CYP450
ric setting, a retrospective study, Pharmacol Res (2016),
Many factors may  be involved in interindividual variability in
drug response, in every step from drug prescription to drug effect
(medications errors and lack of compliance to drug-receptor inter-
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ction and desensitization, for example) [6]. Among them, the
ariability in drug metabolism, which can result in pronounced dif-
erences in steady-state plasma concentrations, may  be predicted
7,8]. Hence, research has focused on the promise of individual-
zed treatment in psychiatry. Different studies have supported a
ink between enzyme/transporter activity and the pharmacokinetic
r pharmacodynamic parameters of antidepressant or antipsy-
hotic agents, suggesting genotyped-based dose recommendations
4,5,7,9,10].
Hall-Flavin et al. recently demonstrated that the prospective
se of a pharmacogenomic testing involving cytochrome P450
CYP450) and an interpretive report was able to improve depres-
ion outcome, by allowing the physicians to select the appropriate
rug in a small cohort of patients presenting with major depres-
ive disorder. However, assessment of drug metabolism variability,
.g CYP450 activity, is not a part of the usual care in practice and
sychiatrists mainly rely on clinical evaluation or therapeutic drug
onitoring (TDM) when available, to start or adapt psychotropic
edication.
To date, data are missing about the usefulness of prospective
ssessment of variability in drug metabolism in psychiatric settings.
n the Geneva University Hospitals, clinical pharmacologists of the
ivision of clinical pharmacology and toxicology daily answer to
hysicians’ questions about adverse drug reactions (ADR), abnor-
al  TDMs, non-response to treatment, or therapeutic management
choice of the drug, dose, route of administration), among other sit-
ations. After analysing the clinical situations and in order to clarify
harmacological abnormalities, genetic or phenotypic investiga-
ions may  be proposed by the clinical pharmacologist, based on his
linical expertise, the clinical context, the nature of the ADR, TDM
r non-response and the concomitant medications, potentially lim-
ting the interpretation of the tests.
In order to better discuss the beneﬁt of investigating patients’
etabolic status during psychiatric therapeutic management and
efore engaging in a prospective study, this retrospective study
imed to assess to what extent an ADR, TDM or non-response was
ttributable to a variant of CYP450 activity when indicated by a
linical pharmacologist,
. Methods
.1. Patients and setting
The division of clinical pharmacology of Geneva University Hos-
itals give pharmacological advices to physicians on individual
linical situations, such as the appropriate drug in case of pregnancy
r breastfeeding, in case of weight gain, in case of drug interactions,
dverse effects or treatment failure, among others.
Questions come from hospitals physicians as well as from
rivate practices, and this for all medical specialities. Individual
ropositions are summarized in a report and when considered
ppropriate by a senior clinical pharmacologist, genetic and/or
henotypic investigations are proposed. If the tests are performed,
heir results are analysed according to the clinical context and
ummarized in a second report. We  retrospectively collected
esults of genetic and/or phenotypic investigations performed
etween January 2005 and November 2014 and selected all data
elated to psychotropic drugs (N = 250). The study was  approved
y the local ethics committee (Reference: 14–244). Data were
xcluded if investigations did not assess all major metabolic path-
ays of the involved drug, according to the table of cytochromePlease cite this article in press as: C. Lloret-Linares, et al., Scr
activity in patients with therapeutic problems in a psychiat
http://dx.doi.org/10.1016/j.phrs.2016.07.002
ubstrates (http://www.hug-ge.ch/sites/interhug/ﬁles/structures/
harmacologie et toxicologie cliniques/documents/substrats et
nhibiteurs a5.pdf) [11]. For example, an investigation related to
italopram was only included if CYP2C19 and CYP3A4 activities PRESS
al Research xxx (2016) xxx–xxx
were studied, CYP1A2 and CYP2D6 for duloxetine, CYP2D6 and
CYP3A4 for haloperidol etc. The ﬂowchart of data inclusion is
illustrated in Fig. 1: 138 therapeutic situations were analysed,
which referred to 89 patients and 34 drugs.
2.2. Evaluation criteria
All clinical pharmacology reports were carefully reviewed and
classiﬁed into different categories according to clinical events,
such as ADR and lack of response to the prescribed drug. Two expe-
rienced clinical pharmacologists assessed the possible association
between these clinical events and the genetic and phenotypic
results independently according to a semi-quantitative scale and
their clinical judgment (Appendix A). The semi-quantitative scale
was mainly built on scientiﬁc databases (e.g. http://www.hugge.
ch/sites/interhug/ﬁles/structures/pharmacologie et toxicologie
cliniques/documents/substrats et inhibiteurs a5; DrugBank,
http://www.drugbank.ca/; ‘The Human Cytochrome P450 (CYP)
Allele Nomenclature Database’, http://cypalleles.ki.se). For a given
drug, each relevant metabolic pathway, whether major or minor,
was considered and a global rating was made according to a
3-point scale: 0 = no or low probability of genetic and pheno-
typic results being linked with a clinical or biological problem;
1 = intermediate probability; 2 = high probability. In case of drugs
with active metabolites, the use of the table was completed by
the available literature on the respective clinical relevance of the
metabolite and the parent compound. In case of disagreement,
the opinion of a third expert in clinical pharmacology was sought
and retained as the ﬁnal score. The patient’s treatment at the time
of the phenotypic and/or genetic investigation was recorded and
taken into account when rating the association between metabolic
status and event.
2.3. Metabolic status
Activities of CYP2D6, 2C9 and 2C19 were assessed by genotyping
and/or phenotyping, whereas activities of CYP1A2 and 3A4 were
only determined by phenotyping.
2.3.1. Genotyping
The following variants of the CYP2D6 gene were genotyped:
CYP2D6*3, *4, *5, *6, *35, *41 and duplications, until 2007, when
the AmpliChip CYP450 test allowed the simultaneous analysis of
33 CYP2D6 alleles. For the CYP2C9 and CYP2C19 genes, the follow-
ing variants were genotyped: CYP2C9 *2 and *3, CYP2C19*2 and *17
(since 2009).
The predicted phenotypes were based on enzyme activities
of these alleles, as listed in ‘The Human Cytochrome P450 (CYP)
Allele Nomenclature Database’ (http://cypalleles.ki.se) or the Phar-
mGKB database (http://www.pharmgkb.org/index.jsp), or in the
AmpliChip CYP450 2D6 test. Patients were classiﬁed as poor metab-
olizer (PM), intermediate metabolizer (IM), extensive metabolizer
(EM) and ultra-rapid metabolizer (UM) for CYP2C19 and CYP2D6
and as induced, normal or reduced activity for CYP2C9.
2.3.2. Phenotyping
Phenotyping consists in the administration of probe sub-
strates metabolised by speciﬁc CYPs and determination of
plasma, blood, or urine metabolic ratios. Probe substrates were
caffeine for CYP1A2, ﬂurbiprofen for CYP2C9, omeprazole for
CYP2C19, dextromethorphan for CYP2D6 and midazolam for
CYP3A4. Individual phenotyping corresponded to the administra-eening for genotypic and phenotypic variations in CYP450
ric setting, a retrospective study, Pharmacol Res (2016),
tion of the CYP2D6-speciﬁc probe, dextromethorphan. Dextror-
phan/dextromethorphan ratio was  measured in urinary samples
during several years based on cut-off data from previous stud-
ies [12,13]. Lately, with the development of dried blood spots
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osages, this method has been rarely performed. Simultaneous
henotyping corresponded to the concomitant administration of
ultiple speciﬁc probes with caffeine 50 mg,  ﬂurbiprofen 10 mg,
extromethorphan 10 mg,  midazolam 1 mg,  bupropion 20 mg  and
meprazole 10 mg.  Capillary blood samples 2 h following drug
dministration allowed measuring the activity of multiple CYP450
nzymes simultaneously, as previously reported [14,15].
Phenotypic classiﬁcation was based on plasma or urine
etabolic ratios according to a validated method developed in the
aboratory of clinical pharmacology and toxicology of the Univer-
ity Hospitals of Geneva [14,16,17]. CYP1A2, 2C9 and 3A4 enzyme
ctivities were categorized as induced, normal or reduced. Those of
YP2C19 and 2D6 allowed classifying patients as poor metabolizer
PM), intermediate metabolizer (IM), extensive metabolizer (EM)
r ultrarapid metabolizer (UM).
.4. Statistical analysis
Categorical and continuous variables were described using fre-
uency tables (N, %) and median (range), respectively. Comparisons
f proportions were performed using Fisher’s exact tests. Inter-
a inter-rater reliability, te reliability of the scoring system was
ssessed with the kappa coefﬁcient. Statistics were computed using
PSS version 22 (IBM Corporation, Armonk, NY). All tests were two-
ailed, with signiﬁcance level at 0.05.
. Results
.1. Patients, ADR, TDM or non-response, and involved drugs
As presented in Fig. 1, between January 2005 and November
014, 695 genotypic or phenotypic explorations were recom-
ended to the patients addressed to the division of clinicalPlease cite this article in press as: C. Lloret-Linares, et al., Scr
activity in patients with therapeutic problems in a psychiat
http://dx.doi.org/10.1016/j.phrs.2016.07.002
harmacology and toxicology. Among them 260 involved ADR,
DM or non-response to psychotropic drugs. One hundred thirty-
ight included then a complete assessment of all major metabolic
athways of the target drug. These assessments were performed inw-Chart.
89 patients (56 women, 33 men), because of one (n = 57) or several
(n = 32) ADR, TDM or non-response.
A majority of clinical or biological situations were observed with
antidepressants (n = 93, 67.4%), followed by antipsychotics (n = 28,
20.3%), benzodiazepines and hypnotics (n = 13, 9.4%), and psychos-
timulants (n = 4, 2.9%). Genotype and/or phenotype determination
was mainly performed because of an ADR (n = 68, 49.3%) or a non-
response (n = 46, 33.3%), followed by abnormal drug concentrations
or metabolic ratio (n = 14, 10%).
3.2. Metabolic status
Patients’ CYP450 activity, assessed by phenotyping and/or geno-
typing, is presented in the Appendix B. Regarding the phenotypic
approach, the most frequently investigated enzymes were CYP2D6
(n = 62 patients), followed by CYP1A2 (n = 46), CYP3A4 (n = 45),
CYP2C9 (n = 42) and CYP2C19 (n = 40). For the genetic approach,
CYP2D6 was  the most frequently studied enzyme (n = 50), fol-
lowed by CYP2C19 (n = 26) and CYP2C9 (n = 17). A large majority of
patients were treated with one or more drugs when phenotyping
was performed (n = 57 of 63 documented cases, 90.5%). Treatment
included CYP2D6 or CYP2C19 inhibitors for 36 (57.1%) and 19
patients (30.2%), respectively.
3.3. Concordance between predicted and measured CYP450
activity
Among the 62 patients who underwent CYP2D6 phenotypic
exploration, 28 were also investigated by a genetic approach. In
53.6% of the cases (15/28), concordance was observed between
genotype and phenotype.
The details of the discordances for CYP2C19 and CYP2D6,eening for genotypic and phenotypic variations in CYP450
ric setting, a retrospective study, Pharmacol Res (2016),
together with the CYP450 inhibitors that may  explain the discor-
dances are presented in Table 1. Five patients with an EM genotype
showed an IM or PM phenotype, among whom 3 were comedicated
with CYP2D6 inhibitors. None of the 4 patients with CYP2D6 UM
ARTICLE IN PRESSG ModelYPHRS-3230; No. of Pages 7
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Table 1
Concordance between predicted phenotype based on genotype and actual phenotype.
Predicted phenotype based on
genotype
Actual phenotype CYP450 Inhibitors possibly relevant to
discordant cases (resulting phenotype)
UM frequency
(%)a
EM frequency
(%)a
IM frequency
(%)a
PM frequency
(%)a
CYP2D6 28
UM 2 0 (0%) 1 1 0 EM = clomipramine,IM = citalopram
EM  20 4 11 (55%) 3 2 IMs  = escitalopram + quetiapine in one
patient/3, ﬂecainide in one patient/3,
PM = paroxetine in one patient/2
IM  4 0 2 2 (50%) 0 EMs: no inductor
PM  2 0 0 0 2 (100%) All concordant cases
CYP2C19 9
EM 6 0 5 (83%) 0 1
0
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a Percent concordance of actual phenotype with predicted phenotype based on g
roﬁle according to phenotype was detected by genotyping, and
one of them was taking a CYP450 inducer.
For CYP2C19, 9 patients were investigated by the two
pproaches. A genotype/phenotype concordance was observed in
5.6% of the cases. In the 4 cases, discordances were observed. In
ne case only, the current treatment with omeprazole may  have
xplained a slower metabolism than genetically predicted (Table 1).
Five patients underwent CYP2C9 assessment by phenotypic
nd genotypic approaches, with 60.0% genotype/phenotype con-
ordance. The two discordant results were not explained by
omedications.
Overall, in 7 cases/11, comedications did not explain the discor-
ances between predicted phenotype and measured phenotype.
.4. Link between metabolic status and ADR, TDM or
on-response
Inter-rater reliability of the scoring system was  excellent
kappa = 0.94), with discrepant results between the two  clini-
al pharmacologists in only 4 of 138 cases. These four cases
ere related to ADR with venlafaxine (two patients, both PM for
YP2C19), ﬂuoxetine (IM for CYP2D6, induced for CYP3A4) and
lomipramine (IM for CYP2D6, induced for CYP1A2 and CYP3A4).
As illustrated in Fig. 2, the probability of a link between ADR,
DM or non-response and metabolic status was rated as interme-
iate to high in 34.7% of all cases (n = 138). For non-response and
DR, proportions were 30.4% and 36.8%, respectively (Fisher’s exact
est, P = 0.55). For concentration or metabolic ratio outside the ther-
peutic range, the proportion was 38.9%. When considering the low
nd high concentrations only, the probability of link was  rated as
ntermediate to high in 30.8% (4/13 cases) and 50% (1/2 cases),
espectively. Cases related to antidepressants were linked to the
enotype or phenotype (intermediate to high probability) in 37.6%
f cases, as compared to 25.0% for antipsychotics (Fisher’s exact
est, P = 0.26).
Table 2 further documents the link between metabolic status
nd non-response or ADR for antidepressants and antipsychotics,
ith examples of each situation. A link was established for 30.8%
f cases related to benzodiazepines and hypnotics, and 50.0% for
sychostimulants.
. DiscussionPlease cite this article in press as: C. Lloret-Linares, et al., Scr
activity in patients with therapeutic problems in a psychiat
http://dx.doi.org/10.1016/j.phrs.2016.07.002
This retrospective study shows that, when indicated by clini-
al pharmacologists, clinical or biological events related to drug
ntake may  be attributable to a variation of the metabolic status
ith an intermediate to high probability in 34.7% of patients on psy- (0%) 2 PM = esomeprazole in one patient/2
pe.
chotropic drugs, based on the congruent retrospective assessment
made by two  clinical pharmacologists.
A decreased or increased CYP450 activity was slightly more fre-
quent when the clinical situation was  an ADR (Fig. 2, Table 2),
compared with non-response. ADR was  easier to identify retro-
spectively by clinical pharmacologist than non-response, which
remained in our retrospective sample an anamnestic subjective
criteria, not systematically assessed by the use of standardized val-
idated questionnaires. Moreover, for most antidepressants, there is
a lack of formal dose-response curve and a delay of at least 8 weeks
is required to observe a positive effect, irrespective of the time
needed to reach the pharmacokinetic steady state. This delay was
not systematically documented in our study, A third reason may
be the fact that management of psychiatric disorders usually rely
on multidisciplinary approaches with non pharmacological ther-
apy, making the link between response and drugs weaker than for
ADRs. This concordance between CYP450 activity and ADRs is in
line with the literature since numerous studies reported an over-
representation of PMs  among patients with antidepressant adverse
events as well as with acute and chronic extrapyramidal ADRs of
antipsychotics at conventional doses [2,6,7,18–21].
In our study, the relevance of pharmacological investigations in
cases of non-response was higher in patients receiving antidepres-
sants than in patients receiving antipsychotics. This is in accordance
with numerous studies showing the better outcome of depression
among patients with CYP2C19 and CYP2D6 PM activity [22–24].
Only few studies on the inﬂuence of metabolism variability on
antipsychotic efﬁcacy have been conducted, and are either negative
or inadequately powered [2,7,18–20,25]. The small sample size of
this retrospective study does not allow drawing conclusion about
the link between metabolism variability and antipsychotic non-
response. But the question is worth to be further explored, since
in our sample of patients on antipsychotic medication, pharmaco-
logical explorations were mainly proposed for treatment failure.
Overall, an abnormal metabolic status was  associated with an ADR,
TDM or non-response with an intermediate to high probability
in 28.2% of cases of antidepressant or antipsychotic non-response
and 37.9% of antidepressant or antipsychotic adverse events. This
is important to consider in situations with therapeutic challenges
such as resistant depression and chronic psychotic diseases, as all
improvement in care would beneﬁt the patient.
In this study, metabolic activity was  largely assessed by a pheno-
typic approach. This method was  often chosen because of its good
efﬁciency and because our laboratory has specialised in a fast, safeeening for genotypic and phenotypic variations in CYP450
ric setting, a retrospective study, Pharmacol Res (2016),
and effective method of assessment. We  have previously shown
the utility of the Dried Blood Spot sampling technique for assess-
ment of the activities of several CYP450 isoforms using a low-dose
phenotyping cocktail and limited blood samples [14]. This method
ARTICLE IN PRESSG ModelYPHRS-3230; No. of Pages 7
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Fig. 2. Prevalence of therapeutic problem attributable to an abnormal metabolic status with an intermediate to high probability according to the therapeutic class and the
clinical  or biological event.
Table 2
Link between type of demand and predicted phenotype based on genotype and/or actual phenotype.
Link with genotype or phenotype a Examples
probability frequency %
Adverse events
Antidepressants (N = 49) intermediate 6 12.2 tachycardia and anxiety with venlafaxine; IM genotype
and phenotype for a major metabolic pathway
(CYP2D6)
high  13 26.5 possible serotonine syndrome with escitalopram; IM
genotype but PM phenotype for a major metabolic
pathway (CYP2C19); IM genotype and phenotype for a
minor pathway (CYP2D6)
Antipsychotics (N = 9) intermediate 2 22.2 excessive sedation with quetiapine; PM genotype and
phenotype for a minor metabolic pathway (CYP2D6)
high  1 11.1 agitation and amnesia with risperidone; PM genotype
for a major metabolic pathway (CYP2D6)
Non-response
Antidepressants (N = 25) intermediate 6 24.0 non-response to trazodone; UM phenotype for a minor
metabolic pathway (CYP2D6)
high 3 12.0 non-response to clomipramine; UM genotype but EM
phenotype for a major metabolic pathway (CYP2D6)
Antipsychotics (N = 14) intermediate 1 7.1 non-response to quetiapine; UM phenotype for a
minor metabolic pathway (CYP2D6)
high  1 7.1 non-response to haloperidol; UM phenotype for a
a
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ta Rating scale is provided in the Appendix.
llows a simultaneous and direct measurement of CYP450 status,
ontrary to the genetic method [14]. Genetic combinatory approach
o CYP2C9, CYP2C19 and CYP2C19 allele scoring was  developed to
acilitate the translation from pharmacogenomics to personalized
edicine and this is particularly valuable in psychiatry where many
rugs are metabolised or bioactivated by multiple CYP450 isoen-
ymes. Besides the high prevalence of patients (52%) with multiple
ene alteration yielding altered drug metabolism supports a major
nterest of the combinatory approach [26]. However, other isoen-
ymes known to play a role in the metabolism of psychotropic
gents, for instance CYP1A2 and CYP3A4, have been excluded from
enetic combinatory approach so far, due to insufﬁcient evidences
o characterize their relevance to psychotropic drug metabolism.Please cite this article in press as: C. Lloret-Linares, et al., Scr
activity in patients with therapeutic problems in a psychiat
http://dx.doi.org/10.1016/j.phrs.2016.07.002
oreover, CYP2D6 genotype analysis remains a challenging task
ue to the large number of allelic variants and the presence of struc-
ural and copy number variation [27]. Several testing platformsmajor metabolic pathway (CYP2D6)
exist but some rare variants or population-speciﬁc allelic variants
may  be missed [27,28]. One further barrier for the implementation
of CYP450 genetic testing into clinical practice is the complexity of
gene locus and genotype interpretation. Although no doubt exists
that genetic variations contribute to the variability of several CYP,
genotyping to predict drug levels is a blunt instrument because of
greater additional variability than those explained by genetics.
Genotype and phenotype can be discordant due to co-
medications [13]. This is illustrated in this study, in the case
of patients with slower measured CYP2D6 activity than those
expected from genotyping. More than a half of these patients
received drugs known to inhibit CYP2D6 at the time of pheno-
typing. Moreover, the genetic approach was  unable to detect 4eening for genotypic and phenotypic variations in CYP450
ric setting, a retrospective study, Pharmacol Res (2016),
CYP2D6 UMs, suggesting that phenotyping is of particular interest
to explore psychiatric patients with ADR, TDM or non-response.
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enotyping also failed to predict some IMs  who had not received
nhibitors, in accordance with a previous study [13].
For all these reasons, phenotypic approach of drug metabolism
ay  be a potent help in personalized medicine even though
ts limits and strengths merit further prospective studies. When
equested and interpreted by a clinical pharmacologist, a careful
nalysis of the medical context allows the choice of the appropri-
te method (genetic or phenotypic approach) and interpretation of
heir results. As a consequence, co-medications should not refrain
he exploration of the metabolic status. In accordance with this,
he high inter-rater reliability between the pharmacologists was
xcellent.
This study presents several limitations due to its retrospective
etting. First of all, plasma drug concentration was available in few
ases, thus, limiting the interpretation of the relationship between
rug metabolism enzymes activity and the clinical situation. Next,
ome discordance between genotype and phenotype was  not elu-
idated. Despite adequate inter-rater reliability, the table used to
core the probability of an association between clinical events and
enetic and phenotypic results has not been validated before. In
articular, it might provide an oversimpliﬁed picture for drugs with
ctive parent compound and metabolite. Accordingly, its use should
e supplemented with literature data and experience in clini-
al pharmacology. The number of studied patients for each drug
emained small, but in each case, the main metabolic pathways
ere systematically studied. Then, feedback that would improve
he probability of the association was missing. Finally, we cannot
xclude that exploring drug metabolism variability would be only
seful in refractory patients, since not all psychiatric patients are
iven specialised pharmacological advice.Please cite this article in press as: C. Lloret-Linares, et al., Scr
activity in patients with therapeutic problems in a psychiat
http://dx.doi.org/10.1016/j.phrs.2016.07.002
In conclusion, we documented, for the ﬁrst time, the part of ADR,
DM or non-response related to drugs that may  be attributable to a
odiﬁed CYP450 activity in a real life setting. As a link was  found in
 third of the cases, TDM coupled with exploration of metabolism
Pro
ph
me
Type of demand UM
Non-response to parent compound (or low concentration) 2 (
Non-response to active metabolite (or low concentration) 0 
Adverse reaction to parent compound (or high concentration) 0 
Adverse reaction to active metabolite (or high concentration) 2 ( PRESS
al Research xxx (2016) xxx–xxx
pathways would certainly be relevant in this challenging psychi-
atric population. The phenotypic approach may  represent a fast,
safe and effective method to simultaneously determine the activ-
ity of several CYPs, giving the opportunity to be clinically applicable
for therapy and taking into account the frequent polymedication
of a real life setting. Since metabolic ratio have not been for-
mally validated in the presence of on-going drug treatment and
since compliance could never been ruled out, TDM, when avail-
able, as well as phenotypic and genotypic determination of CYP450
activity should be integrated in a multidisciplinary approach
involving clinical pharmacologists and psychiatrists. Nevertheless
these techniques would certainly have a place to retrospectively
assess causes of resistance or of unbearable adverse effects and to
tailor therapy.
Further studies evaluating the beneﬁt of these investigations,
according to the drugs, the adverse drug reactions and the degree of
non-response using validated questionnaires, would help to deﬁne
the most relevant clinical situations for phenotypic and geno-
typic investigations, and to draw conclusions about the prospective
and/or retrospective clinical utility of CYP-typing in a psychiatric
setting.
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Appendix A. : Rating scale for the link between type of
demand and predicted phenotype based on diplotype
and/or actual phenotype
bability of link according to
enotype for major (minor)
tabolic pathway
 EM IM PM
1) 0 0 0
0 1 (0) 2 (1)
0 1 (0) 2 (1)
1) 0 0 0
For a given drug, consider each relevant metabolic pathway,
whether major or minor. Rate each pathway according to the table
above, with 0 = no or low probability of link with clinical problem;
1 = intermediate probability; 2 = high probability. The total score is
obtained by adding the scores for all relevant pathways (if sum > 2,
consider a total score of 2). In case of drugs with active metabo-
lites, the use of the table was completed by the available literature
on the respective clinical relevance of the metabolite and the parent
compound.eening for genotypic and phenotypic variations in CYP450
ric setting, a retrospective study, Pharmacol Res (2016),
Appendix B. : Predicted phenotype based on diplotype and
actual phenotype (N = 89 patients)
 IN PRESSG ModelY
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P Genotype Phenotype
Frequency % Frequency %
C N = 50 N = 62
U 3 6.0 11 17.7
E *2/*10, *2/*35, *2/*41, *2xN/*4 36 72.0 27 43.5
I 6 12.0 12 19.4
P 5 10.0 12 19.4
C N = 17 N = 42
i 0 0.0 6 14.3
n 12 70.6 31 73.8
r 5 29.4 5 11.9
C N = 26 N = 40
U 0 0.0 1 2.5
E 15 57.7 31 77.5
I 9 34.6 1 2.5
P 2 7.7 7 17.5
C N = 46
i 17 37.0
n 28 60.9
r 1 2.2
C N = 45
i 6 13.3
n 36 80.0
r
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